|
WO2009095742A1
(en)
|
2008-01-31 |
2009-08-06 |
Cellectis |
New i-crei derived single-chain meganuclease and uses thereof
|
|
WO2003078619A1
(en)
†
|
2002-03-15 |
2003-09-25 |
Cellectis |
Hybrid and single chain meganucleases and use thereof
|
|
EP2660317B1
(en)
|
2007-10-31 |
2016-04-06 |
Precision Biosciences, Inc. |
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
|
|
US9404099B2
(en)
|
2009-11-27 |
2016-08-02 |
Basf Plant Science Company Gmbh |
Optimized endonucleases and uses thereof
|
|
JP2013511979A
(ja)
|
2009-11-27 |
2013-04-11 |
ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー |
キメラエンドヌクレアーゼおよびその使用
|
|
EP2504429B1
(en)
|
2009-11-27 |
2016-04-20 |
BASF Plant Science Company GmbH |
Chimeric endonucleases and uses thereof
|
|
WO2011117249A1
(en)
|
2010-03-22 |
2011-09-29 |
Philip Morris Products S.A. |
Modifying enzyme activity in plants
|
|
WO2012138901A1
(en)
*
|
2011-04-05 |
2012-10-11 |
Cellectis Sa |
Method for enhancing rare-cutting endonuclease efficiency and uses thereof
|
|
DK3489366T3
(da)
|
2011-06-01 |
2020-02-24 |
Prec Biosciences Inc |
Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener
|
|
EP2612918A1
(en)
|
2012-01-06 |
2013-07-10 |
BASF Plant Science Company GmbH |
In planta recombination
|
|
WO2013166113A1
(en)
*
|
2012-05-04 |
2013-11-07 |
E. I. Du Pont De Nemours And Company |
Compositions and methods comprising sequences having meganuclease activity
|
|
US20170106055A1
(en)
|
2014-03-12 |
2017-04-20 |
Precision Biosciences, Inc. |
Dystrophin Gene Exon Deletion Using Engineered Nucleases
|
|
IL292574A
(en)
|
2014-09-07 |
2022-06-01 |
Selecta Biosciences Inc |
Methods and compositions for attenuating anti-viral transfer vector immune responses
|
|
EP4015633A1
(en)
|
2015-05-01 |
2022-06-22 |
Precision Biosciences, Inc. |
Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion disorders using engineered nucleases
|
|
FI3447075T3
(fi)
|
2015-05-15 |
2023-11-07 |
Massachusetts Gen Hospital |
Antagonistisia anti-tuumorinekroositekijäreseptorin superperheen vasta-aineita
|
|
WO2016205825A1
(en)
|
2015-06-19 |
2016-12-22 |
Precision Biosciences, Inc. |
Self-limiting viral vectors encoding nucleases
|
|
EP3313420B1
(en)
|
2015-06-25 |
2024-03-13 |
The Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
|
|
EP3334750B1
(en)
|
2015-08-11 |
2022-10-05 |
Anie Philip |
Peptidic tgf-beta antagonists
|
|
AU2016321244B2
(en)
|
2015-09-08 |
2020-09-24 |
Precision Biosciences, Inc. |
Treatment of retinitis pigmentosa using engineered meganucleases
|
|
KR20250013291A
(ko)
|
2015-10-05 |
2025-01-31 |
프리시젼 바이오사이언시스 인코포레이티드 |
변형된 인간 t 세포 수용체 알파 불변 영역 유전자를 포함하는 유전자 변형된 세포
|
|
EP3940070A1
(en)
*
|
2015-10-05 |
2022-01-19 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
|
|
ES2901000T3
(es)
|
2015-12-23 |
2022-03-21 |
Prec Biosciences Inc |
Meganucleasas de ingeniería con secuencias de reconocimiento encontradas en el gen de la microglobulina beta-2 humana
|
|
US11274288B2
(en)
|
2016-02-16 |
2022-03-15 |
Emendobio Inc. |
Compositions and methods for promoting homology directed repair mediated gene editing
|
|
AU2017235461B2
(en)
|
2016-03-15 |
2023-02-23 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion
|
|
GB2570382B
(en)
|
2016-04-27 |
2020-07-29 |
Univ Puerto Rico |
1,5-disubstituted 1,2,3-triazoles are inhibitors of Rac/Cdc42 GTPases
|
|
DK3452583T3
(da)
|
2016-05-03 |
2022-01-10 |
Prec Biosciences Inc |
Konstruerede nukleaser, der er nyttige til behandling af hæmofili a
|
|
MX2018015798A
(es)
|
2016-06-22 |
2019-07-12 |
Univ North Carolina State |
Método para incrementar la eficiencia de uso de nitrógeno y/o la eficiencia de utilización de nitrógeno en plantas.
|
|
AU2017301609A1
(en)
*
|
2016-07-25 |
2019-02-21 |
Bluebird Bio, Inc. |
BCL11A homing endonuclease variants, compositions, and methods of use
|
|
EP3504335A4
(en)
|
2016-08-23 |
2020-04-15 |
Bluebird Bio, Inc. |
HOMING TIM3 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
|
|
CA3035455A1
(en)
|
2016-09-08 |
2018-03-15 |
Bluebird Bio, Inc. |
Pd-1 homing endonuclease variants, compositions, and methods of use
|
|
ES2811500T3
(es)
|
2016-10-04 |
2021-03-12 |
Prec Biosciences Inc |
Dominios coestimuladores para su uso en células genéticamente modificadas
|
|
PE20191353A1
(es)
|
2016-10-14 |
2019-10-01 |
Prec Biosciences Inc |
Meganucleasas disenadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b
|
|
AU2017346683B2
(en)
*
|
2016-10-17 |
2024-04-18 |
Regeneron Pharmaceuticals, Inc. |
TGFβR2 endonuclease variants, compositions, and methods of use
|
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
IL293956A
(en)
|
2017-04-12 |
2022-08-01 |
Magenta Therapeutics Inc |
Aryl hydrocarbon receptor antagonist and its uses
|
|
ES2953153T3
(es)
|
2017-04-21 |
2023-11-08 |
Prec Biosciences Inc |
Meganucleasas diseñadas específicas para secuencias de reconocimiento en el gen pcsk9
|
|
EP3615662A1
(en)
|
2017-04-28 |
2020-03-04 |
Precision Biosciences, Inc. |
Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells
|
|
JP7170666B2
(ja)
|
2017-05-08 |
2022-11-14 |
プレシジョン バイオサイエンシズ,インク. |
操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法
|
|
JP7191042B2
(ja)
|
2017-05-25 |
2022-12-16 |
2セブンティ バイオ インコーポレイテッド |
Cblbエンドヌクレアーゼバリアント、組成物、および使用方法
|
|
MX2019015413A
(es)
|
2017-06-23 |
2020-07-20 |
Univ Kentucky Res Found |
Metodo.
|
|
CA3068465A1
(en)
|
2017-06-30 |
2019-01-03 |
Precision Biosciences, Inc. |
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
|
JP2020529206A
(ja)
|
2017-07-31 |
2020-10-08 |
アール・ジエイ・レイノルズ・タバコ・カンパニー |
植物におけるウイルスベースの遺伝子編集のための方法及び組成物
|
|
EP3692057B9
(en)
|
2017-10-03 |
2023-10-04 |
Precision BioSciences, Inc. |
Modified epidermal growth factor receptor peptides for use in genetically-modified cells
|
|
WO2019070974A1
(en)
*
|
2017-10-04 |
2019-04-11 |
Bluebird Bio, Inc. |
PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
|
|
KR20200086670A
(ko)
|
2017-10-13 |
2020-07-17 |
셀렉타 바이오사이언시즈, 인크. |
항바이러스 전달 벡터 IgM 반응을 약화시키기 위한 방법 및 조성물
|
|
US20190343885A1
(en)
|
2017-10-31 |
2019-11-14 |
Magenta Therapeutics Inc. |
Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
|
|
CA3079405A1
(en)
|
2017-10-31 |
2019-05-09 |
Magenta Therapeutics Inc. |
Compositions and methods for the expansion of hematopoietic stem and progenitor cells
|
|
US20200299658A1
(en)
|
2017-11-01 |
2020-09-24 |
Precision Biosciences, Inc. |
Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
|
|
SG11202004913TA
(en)
|
2017-12-06 |
2020-06-29 |
Magenta Therapeutics Inc |
Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
|
|
US20210002621A1
(en)
*
|
2017-12-20 |
2021-01-07 |
Bluebird Bio, Inc. |
Ctla4 homing endonuclease variants, compositions, and methods of use
|
|
US20200338132A1
(en)
|
2018-01-03 |
2020-10-29 |
Magenta Therapeutics Inc. |
Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
|
|
US11359208B2
(en)
|
2018-01-09 |
2022-06-14 |
Cibus Us Llc |
Shatterproof genes and mutations
|
|
KR20200139679A
(ko)
|
2018-02-26 |
2020-12-14 |
안톨알엑스, 인크. |
면역관용성 리포솜 및 그의 사용 방법
|
|
AU2019247403B2
(en)
|
2018-04-04 |
2025-04-10 |
Cibus Europe, B.V. |
FAD2 genes and mutations
|
|
IT201800004253A1
(it)
|
2018-04-05 |
2019-10-05 |
|
Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria.
|
|
IL277883B2
(en)
|
2018-04-12 |
2023-12-01 |
Prec Biosciences Inc |
Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
EP3784790A4
(en)
*
|
2018-04-27 |
2022-02-09 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
BRUTON TYROSINE KINASE HOMING ENDONUCLEAR VARIANTS, COMPOSITIONS AND METHOD OF USE
|
|
AU2019287720B2
(en)
|
2018-06-14 |
2025-08-28 |
Regeneron Pharmaceuticals, Inc. |
CD79A chimeric antigen receptors
|
|
GB201812603D0
(en)
|
2018-08-02 |
2018-09-19 |
British American Tobacco Investments Ltd |
Method
|
|
WO2020051207A2
(en)
|
2018-09-04 |
2020-03-12 |
Magenta Therapeutics Inc. |
Aryl hydrocarbon receptor antagonists and methods of use
|
|
WO2020072059A1
(en)
*
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
GB201817971D0
(en)
|
2018-11-02 |
2018-12-19 |
British American Tobacco Investments Ltd |
Method
|
|
GB201818715D0
(en)
|
2018-11-16 |
2019-01-02 |
British American Tobacco Investments Ltd |
Method
|
|
US12404500B2
(en)
|
2018-12-10 |
2025-09-02 |
Novo Nordisk A/S |
Homing endonuclease variants
|
|
US20220090047A1
(en)
|
2018-12-21 |
2022-03-24 |
Precision Biosciences, Inc. |
Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
|
|
GB201900940D0
(en)
|
2019-01-23 |
2019-03-13 |
British American Tobacco Investments Ltd |
Method
|
|
KR20240122580A
(ko)
|
2019-04-03 |
2024-08-12 |
프리시젼 바이오사이언시스 인코포레이티드 |
마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
|
|
CA3136265A1
(en)
|
2019-04-05 |
2020-10-08 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
|
CN120843482A
(zh)
|
2019-05-07 |
2025-10-28 |
精密生物科学公司 |
用于识别序列的工程化大范围核酸酶的优化
|
|
GB201906768D0
(en)
|
2019-05-14 |
2019-06-26 |
British American Tobacco Investments Ltd |
Method
|
|
CN114206396A
(zh)
|
2019-05-28 |
2022-03-18 |
西莱克塔生物科技公司 |
用于减弱抗病毒转移载体免疫应答的方法和组合物
|
|
GB201909562D0
(en)
|
2019-07-03 |
2019-08-14 |
British American Tobacco Investments Ltd |
Method
|
|
GB201909563D0
(en)
|
2019-07-03 |
2019-08-14 |
British American Tobacco Investments Ltd |
Method
|
|
CA3148179A1
(en)
|
2019-08-20 |
2021-02-25 |
Bruce J. Mccreedy Jr. |
Lymphodepletion dosing regimens for cellular immunotherapies
|
|
US20220411479A1
(en)
|
2019-10-30 |
2022-12-29 |
Precision Biosciences, Inc. |
Cd20 chimeric antigen receptors and methods of use for immunotherapy
|
|
WO2021087406A1
(en)
|
2019-11-01 |
2021-05-06 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progentor cells
|
|
DK4069729T3
(da)
|
2019-12-06 |
2025-04-07 |
Prec Biosciences Inc |
Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
|
|
EP3835309A1
(en)
|
2019-12-13 |
2021-06-16 |
KWS SAAT SE & Co. KGaA |
Method for increasing cold or frost tolerance in a plant
|
|
WO2021158915A1
(en)
|
2020-02-06 |
2021-08-12 |
Precision Biosciences, Inc. |
Recombinant adeno-associated virus compositions and methods for producing and using the same
|
|
KR20220165764A
(ko)
|
2020-04-09 |
2022-12-15 |
아아르. 제이. 레날드즈 토바코 캄파니 |
니코티아나 타바쿰에서 니코틴 수준을 조절하는 방법
|
|
CN115997009A
(zh)
|
2020-04-27 |
2023-04-21 |
美真达治疗公司 |
用于在体内转导造血干细胞和祖细胞的方法和组合物
|
|
WO2021231259A1
(en)
|
2020-05-11 |
2021-11-18 |
Precision Biosciences, Inc. |
Self-limiting viral vectors encoding nucleases
|
|
BR112022022212A2
(pt)
|
2020-05-12 |
2022-12-13 |
Univ Pennsylvania |
Composições para redução específica de drg de expressão de transgene
|
|
EP4150068A1
(en)
|
2020-05-12 |
2023-03-22 |
Precision BioSciences, Inc. |
Treatment of retinitis pigmentosa using improved engineered meganucleases
|
|
WO2022035793A1
(en)
|
2020-08-10 |
2022-02-17 |
Precision Biosciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
|
US20240011003A1
(en)
|
2020-08-21 |
2024-01-11 |
Precision Biosciences, Inc. |
Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene
|
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
|
JP2023550581A
(ja)
|
2020-10-29 |
2023-12-04 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Aavカプシド及びそれを含有する組成物
|
|
CA3172481A1
(en)
|
2020-11-12 |
2022-05-19 |
Precision Biosciences, Inc. |
Engineered meganucleases having specificity for recognition sequences in the dystrophin gene
|
|
CA3172161A1
(en)
|
2021-01-08 |
2022-07-14 |
James Jefferson Smith |
Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene
|
|
US20250127811A1
(en)
|
2021-01-28 |
2025-04-24 |
Precision Biosciences, Inc. |
Modulation of tgf beta signaling in genetically-modified eukaryotic cells
|
|
WO2022197776A1
(en)
|
2021-03-16 |
2022-09-22 |
Magenta Therapeutics, Inc. |
Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
|
|
AU2022262778A1
(en)
|
2021-04-22 |
2023-11-30 |
Precision Biosciences, Inc. |
Engineered meganucleases that target human mitochondrial genomes
|
|
WO2022226316A1
(en)
|
2021-04-22 |
2022-10-27 |
Precision Biosciences, Inc. |
Compositions and methods for generating male sterile plants
|
|
CA3173245A1
(en)
|
2021-04-22 |
2022-10-22 |
James Jefferson Smith |
Engineered meganucleases that target human mitochondrial genomes
|
|
AR125467A1
(es)
|
2021-04-27 |
2023-07-19 |
Univ Pennsylvania |
Cápsides de virus adenoasociados derivados de porcinos y usos de los estos
|
|
US20230141563A1
(en)
|
2021-10-12 |
2023-05-11 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
|
EP4419660A2
(en)
|
2021-10-19 |
2024-08-28 |
Precision BioSciences, Inc. |
Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
|
|
EP4419111A1
(en)
|
2021-10-19 |
2024-08-28 |
Precision Biosciences, Inc. |
Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
|
|
US20250295807A1
(en)
|
2021-11-15 |
2025-09-25 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
AU2023214690A1
(en)
|
2022-02-03 |
2024-08-15 |
Nicoventures Trading Limited |
Method of modulating alkaloid content in tobacco plants
|
|
AU2023215810A1
(en)
|
2022-02-03 |
2024-08-15 |
Nicoventures Trading Limited |
Method of modulating alkaloid content in tobacco plants
|
|
MX2024009605A
(es)
|
2022-02-04 |
2024-08-14 |
Nicoventures Trading Ltd |
Metodo para modular el contenido de alcaloides en plantas de tabaco.
|
|
US20230357437A1
(en)
|
2022-03-09 |
2023-11-09 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
|
GB202205149D0
(en)
|
2022-04-07 |
2022-05-25 |
Nicoventures Trading Ltd |
Method
|
|
GB202205148D0
(en)
|
2022-04-07 |
2022-05-25 |
Nicoventures Trading Ltd |
Method
|
|
GB202205561D0
(en)
|
2022-04-14 |
2022-06-01 |
Nicoventures Trading Ltd |
Method
|
|
GB202205562D0
(en)
|
2022-04-14 |
2022-06-01 |
Nicoventures Trading Ltd |
Method
|
|
GB202206109D0
(en)
|
2022-04-27 |
2022-06-08 |
Nicoventures Trading Ltd |
Method
|
|
GB202206107D0
(en)
|
2022-04-27 |
2022-06-08 |
Nicoventures Trading Ltd |
Method
|
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
|
WO2024015966A2
(en)
|
2022-07-15 |
2024-01-18 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav having aav clade d and clade e capsids and compositions containing same
|
|
WO2024056902A2
(en)
|
2022-09-16 |
2024-03-21 |
Christopher Shaw |
Compositions and methods for treating neurological diseases
|
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|
|
WO2024126696A1
(en)
|
2022-12-14 |
2024-06-20 |
King's College London |
Compositions and methods for treating neurological diseases
|
|
EP4646223A1
(en)
|
2023-01-05 |
2025-11-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
|
|
GB202300905D0
(en)
|
2023-01-20 |
2023-03-08 |
Nicoventures Trading Ltd |
Method
|
|
WO2024161022A2
(en)
|
2023-02-03 |
2024-08-08 |
King's College London |
Compositions and methods for treating neurological diseases
|
|
CN120641566A
(zh)
|
2023-02-06 |
2025-09-12 |
蓝岩治疗有限公司 |
降解决定子融合蛋白及其产生方法和用途
|
|
GB202303077D0
(en)
|
2023-03-02 |
2023-04-19 |
Univ Oslo |
Brassica plants with improved seed retention
|
|
IL322995A
(en)
|
2023-03-02 |
2025-10-01 |
Alloy Therapeutics Inc |
Anti-CD22 antibodies and their uses
|
|
WO2024216118A1
(en)
|
2023-04-14 |
2024-10-17 |
Precision Biosciences, Inc. |
Muscle-specific expression cassettes
|
|
WO2024216116A1
(en)
|
2023-04-14 |
2024-10-17 |
Precision Biosciences, Inc. |
Muscle-specific expression cassettes
|
|
WO2024236547A1
(en)
|
2023-05-18 |
2024-11-21 |
Inceptor Bio, Llc |
Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
|
|
WO2025046513A1
(en)
|
2023-08-29 |
2025-03-06 |
Inceptor Bio, Llc |
Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
|
|
WO2025083169A1
(en)
|
2023-10-17 |
2025-04-24 |
Tenpoint Therapeutics Limited |
Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders
|
|
WO2025101946A1
(en)
*
|
2023-11-08 |
2025-05-15 |
Precision Biosciences, Inc. |
Polypeptide linkers for use in engineered meganucleases
|
|
WO2025126153A2
(en)
|
2023-12-14 |
2025-06-19 |
Aviadobio Ltd. |
Compositions and methods for treating sod1-mediated neurological diseases
|
|
WO2025233894A1
(en)
|
2024-05-09 |
2025-11-13 |
University Of Miami |
Engineered meganucleases that target human mitochondrial genomes
|